As expected, BRAFi-resistant melanoma cell lines A375RES and SkMel28RES showed a high proliferation rate despite treatment with vemurafenib at 2 μM or the MEK inhibitor cobimetinib at 0.4 μM while the proliferation of parental cell lines was strongly inhibited (Figure 2A). This evidence concerns the gene MAP2K7 and melanoma.